Skip to main content
Interview with the Innovators

Epidemiology and expected survivorship in follicular lymphoma and lack of reliable long-term outcome predictors at disease presentation

Tycel J. Phillips, MD
Clinical Associate Professor
University of Michigan Rogel Cancer Center
Ann Arbor, MI
Peg Rummel, MHA, RN, OCN, NE-BC
Oncology Nurse Navigator
Hematology/Head & Neck Clinical Services
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA
Andrew D. Zelenetz, MD, PhD
Medical Oncologist and Medical Director
Quality Informatics, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Cornell Medical College Chair, Lymphoma Research Foundation, Scientific Advisory Board
New York, NY

Dr Andrew Zelenetz presents key aspects of the epidemiology of, and currently achieved survivorship in, follicular lymphoma (FL) and compares them with those seen in more commonly diagnosed malignancies treated by the broader group of community-based medical oncologists. Dr Tycel Phillips comments on the paucity of patient features or disease attributes that would help predict poor clinical outcomes, including reduced survival, when FL patients are evaluated at the time of initial diagnosis.

Supported by

Related Items